Literature DB >> 35031951

Semaphorin-3A: a promising therapeutic tool in allergic rhinitis.

Ramin Lotfi1,2, Nahid Zamanimehr3,4.   

Abstract

Semaphorin-3A (Sema-3A), a secreted member of the semaphorin family, is well known for playing regulatory functions at all stages of the immune response. Sema-3A transduces signals by binding to its cognate receptors, namely, class A plexins (Plxns A1 to A4) and neuropilin-1 (Nrp-1). The downstream diverse signaling pathways induced by connecting Sema-3A to its receptors were found to be involved in the pathogenesis of different immunological disorders, ranging from cancer to autoimmunity and allergies. Recent studies have demonstrated that Sema-3A expression is diminished in the murine models and patients with allergic rhinitis (AR; a chronic inflammatory disorder of the nasal mucosa), suggesting the involvement of Sema-3A in AR pathogenesis. Investigations also revealed that treatment of these mice with exogenous Sema-3A protein alleviates the clinical symptom scores of AR, thereby compensating for the reduced expression of Sema-3A in AR. Indeed, Sema-3A treatment could suppress allergic responses in AR via inhibiting Th2/Th17 responses and boosting Th1/Treg responses. Also, Sema-3A could diminish dendritic cell (DC) maturation and T cell proliferation. Since it is implicated in the pathogenesis of AR; thus, Sema-3A turns to be a promising tool of therapy to be studied and utilized in this disease. This review intends to highlight the recent evidence on the role of Sema-3A in AR pathogenesis and summarizes the recent findings regarding the expression status of Sema-3A, as well as its therapeutic potential for treating this disease. HIGHLIGHTS: Sema-3A plays regulatory functions at all stages of the immune response. Sema-3A receptors are the class A plexins (A1-A4) and neuropilin-1 (Nrp-1). Sema-3A expression is reduced in murine models and patients with allergic rhinitis. Connecting Sema-3A to Nrp-1 increases Foxp3 expression in Treg cells. Injecting Sema-3A protein exerts therapeutic effects in mouse models of allergic diseases. Sema-3A shows promise as a therapeutic tool for the treatment of allergic rhinitis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Allergic rhinitis; Class A plexins; Neuropilin-1; Semaphorin-3A; Therapeutic

Mesh:

Substances:

Year:  2022        PMID: 35031951     DOI: 10.1007/s12026-022-09264-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  45 in total

Review 1.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).

Authors:  J Bousquet; N Khaltaev; A A Cruz; J Denburg; W J Fokkens; A Togias; T Zuberbier; C E Baena-Cagnani; G W Canonica; C van Weel; I Agache; N Aït-Khaled; C Bachert; M S Blaiss; S Bonini; L-P Boulet; P-J Bousquet; P Camargos; K-H Carlsen; Y Chen; A Custovic; R Dahl; P Demoly; H Douagui; S R Durham; R Gerth van Wijk; O Kalayci; M A Kaliner; Y-Y Kim; M L Kowalski; P Kuna; L T T Le; C Lemiere; J Li; R F Lockey; S Mavale-Manuel; E O Meltzer; Y Mohammad; J Mullol; R Naclerio; R E O'Hehir; K Ohta; S Ouedraogo; S Palkonen; N Papadopoulos; G Passalacqua; R Pawankar; T A Popov; K F Rabe; J Rosado-Pinto; G K Scadding; F E R Simons; E Toskala; E Valovirta; P van Cauwenberge; D-Y Wang; M Wickman; B P Yawn; A Yorgancioglu; O M Yusuf; H Zar; I Annesi-Maesano; E D Bateman; A Ben Kheder; D A Boakye; J Bouchard; P Burney; W W Busse; M Chan-Yeung; N H Chavannes; A Chuchalin; W K Dolen; R Emuzyte; L Grouse; M Humbert; C Jackson; S L Johnston; P K Keith; J P Kemp; J-M Klossek; D Larenas-Linnemann; B Lipworth; J-L Malo; G D Marshall; C Naspitz; K Nekam; B Niggemann; E Nizankowska-Mogilnicka; Y Okamoto; M P Orru; P Potter; D Price; S W Stoloff; O Vandenplas; G Viegi; D Williams
Journal:  Allergy       Date:  2008-04       Impact factor: 13.146

Review 2.  The role of immune semaphorins in the pathogenesis of multiple sclerosis: Potential therapeutic targets.

Authors:  Ramin Lotfi; Rasoul Nasiri Kalmarzi; Misagh Rajabinejad; Sabah Hasani; Fatemeh Zamani
Journal:  Int Immunopharmacol       Date:  2021-03-20       Impact factor: 4.932

Review 3.  Semaphorins and Their Roles in Airway Biology: Potential as Therapeutic Targets.

Authors:  Hesam Movassagh; Forough Khadem; Abdelilah S Gounni
Journal:  Am J Respir Cell Mol Biol       Date:  2018-01       Impact factor: 6.914

4.  Response of peripheral blood Th17 cells to inhaled Dermatophagoides pteronyssinus in patients with allergic rhinitis and asthma.

Authors:  Ieva Bajoriuniene; Kestutis Malakauskas; Simona Lavinskiene; Jolanta Jeroch; Edita Gasiuniene; Astra Vitkauskiene; Raimundas Sakalauskas
Journal:  Lung       Date:  2012-07-28       Impact factor: 2.584

5.  Allergic Rhinitis: an Overview.

Authors:  Jitendra Varshney; Himanshu Varshney
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2015-01-31

Review 6.  Immunological functions of the neuropilins and plexins as receptors for semaphorins.

Authors:  Atsushi Kumanogoh; Hitoshi Kikutani
Journal:  Nat Rev Immunol       Date:  2013-11       Impact factor: 53.106

Review 7.  The role of immune semaphorins in multiple sclerosis.

Authors:  Tatsusada Okuno; Yuji Nakatsuji; Atsushi Kumanogoh
Journal:  FEBS Lett       Date:  2011-03-22       Impact factor: 4.124

Review 8.  The role of semaphorins in immune responses and autoimmune rheumatic diseases.

Authors:  Masayuki Nishide; Atsushi Kumanogoh
Journal:  Nat Rev Rheumatol       Date:  2017-12-07       Impact factor: 20.543

9.  Association of interleukin-12B rs6887695 with susceptibility to allergic rhinitis.

Authors:  Sara Falahi; Farhad Salari; Alireza Rezaiemanesh; Seyed Hamidreza Mortazavi; Farzaneh Koohyanizadeh; Ramin Lotfi; Ali Gorgin Karaji
Journal:  Immunol Res       Date:  2021-04-08       Impact factor: 2.829

10.  An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011.

Authors:  X D Wang; M Zheng; H F Lou; C S Wang; Y Zhang; M Y Bo; S Q Ge; N Zhang; L Zhang; C Bachert
Journal:  Allergy       Date:  2016-04-13       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.